Elizabeth H. Stover

Publication List Details

Period

2003 - 2006

Number

12

Co-Authors

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant (2006)

Folens, Cedric, Stover, Elizabeth H, ...

The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib. FIP1L1-PDGFRA-positive patients with CEL...

Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia (2006)

Stover, Elizabeth H, Gilliland, D Gary CORA

Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are related hematological malignancies characterized by sustained, unexplained hypereosinophilia (>1,500...

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia (2003)

Stover, Elizabeth H, Gilliland, D Gary

PURPOSE OF REVIEW: The idiopathic hypereosinophilic syndrome is a rare hematologic disorder characterized by sustained unexplained eosinophilia with associated end-organ damage and by a striking male...

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease (2003)

Stover, Elizabeth H, Boulton, Christina L, Gotlib, Jason, Legare, Robert D, Amaral, Sonia M, ...

FIP1L1-PDGFRalpha causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib (Gleevec). Imatinib is a potent inhibitor of ABL, ARG, PDGFRalpha, PDGFRbeta, and...

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome (2003)

Cools, Jan, DeAngelo, Daniel J., Gotlib, Jason, Stover, Elizabeth H., Legare, Robert D., Cortes, Jorges, ...

BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome (2003)

DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, ...

BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome (2003)

Cools, Jan, DeAngelo, Daniel J., Gotlib, Jason, Stover, Elizabeth. H., Legare, Robert. D., Cortes, Jorges, ...

BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...

Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

Stover, Elizabeth H., Chen, Jing, Folens, Cedric, Lee, Benjamin H., Mentens, Nicole, Marynen, Peter, ...

Genetic abnormalities that result in expression of chimeric tyrosine kinase proteins such as BCR-ABL1 and ETV6-PDGFRβ are common causes of hematopoietic malignancies. The paradigm for constitutive...

Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

Stover, Elizabeth H., Chen, Jing, Folens, Cedric, Lee, Benjamin H., Mentens, Nicole, Marynen, Peter, ...

Genetic abnormalities that result in expression of chimeric tyrosine kinase proteins such as BCR-ABL1 and ETV6-PDGFRβ are common causes of hematopoietic malignancies. The paradigm for constitutive...

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

Stover, Elizabeth H., Chen, Jing, Lee, Benjamin H., Cools, Jan, McDowell, Elizabeth, Adelsperger, Jennifer, ...

AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint cluster region-abelson (BCR-ABL). We tested its effectiveness against fusion...

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Lierman, Els, Folens, Cedric, Stover, Elizabeth H., Mentens, Nicole, Van Miegroet, Helen, Scheers, Werner, ...

The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib. FIP1L1-PDGFRA–positive patients with CEL...